| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | 227.04M |
| Revenue Growth % | - | 0.41% | 3.09% | 0.52% | -0.47% | -0.1% |
| Cost of Goods Sold | 0 | 15.61M | 129.69M | 204.22M | 54.01M | 38.55M |
| COGS % of Revenue | - | 0.2% | 0.41% | 0.43% | 0.21% | 0.17% |
| Gross Profit | 54.18M | 61.05M | 184.15M | 273.49M | 197.45M | 188.49M |
| Gross Margin % | 1% | 0.8% | 0.59% | 0.57% | 0.79% | 0.83% |
| Gross Profit Growth % | - | 0.13% | 2.02% | 0.49% | -0.28% | -0.05% |
| Operating Expenses | 125.78M | 198.07M | 2.01B | 2.48B | 1.06B | 748.25M |
| OpEx % of Revenue | 2.32% | 2.58% | 6.41% | 5.2% | 4.22% | 3.3% |
| Selling, General & Admin | 29.48M | 38.31M | 862.95M | 1.43B | 385.02M | 246.16M |
| SG&A % of Revenue | 0.54% | 0.5% | 2.75% | 2.99% | 1.53% | 1.08% |
| Research & Development | 96.3M | 159.77M | 1.15B | 1.05B | 580.62M | 424.06M |
| R&D % of Revenue | 1.78% | 2.08% | 3.66% | 2.2% | 2.31% | 1.87% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 96.21M | 78.03M |
| Operating Income | -71.6M | -137.03M | -1.83B | -2.21B | -864.41M | -559.76M |
| Operating Margin % | -1.32% | -1.79% | -5.83% | -4.62% | -3.44% | -2.47% |
| Operating Income Growth % | - | -0.91% | -12.34% | -0.21% | 0.61% | 0.35% |
| EBITDA | -60.84M | -123.16M | -1.8B | -2.15B | -792.85M | -496.74M |
| EBITDA Margin % | -1.12% | -1.61% | -5.73% | -4.5% | -3.15% | -2.19% |
| EBITDA Growth % | - | -1.02% | -13.61% | -0.19% | 0.63% | 0.37% |
| D&A (Non-Cash Add-back) | 10.76M | 13.86M | 29.08M | 61.63M | 71.55M | 63.02M |
| EBIT | -117.41M | -122.45M | -1.84B | -2.12B | -892.85M | -547.41M |
| Net Interest Income | 3.33M | 197K | -1.54M | 20.16M | 57.12M | 38.52M |
| Interest Income | 5.76M | 2.58M | 837K | 20.26M | 57.22M | 38.61M |
| Interest Expense | 2.42M | 2.38M | 2.37M | 106K | 93K | 94K |
| Other Income/Expense | -48.24M | 12.19M | -9.65M | 87.55M | -28.53M | 12.25M |
| Pretax Income | -119.83M | -124.83M | -1.84B | -2.12B | -892.94M | -547.51M |
| Pretax Margin % | -2.21% | -1.63% | -5.86% | -4.44% | -3.55% | -2.41% |
| Income Tax | 22K | 1.89M | -1.48M | -15.03M | -71K | -479K |
| Effective Tax Rate % | 1% | 1.01% | 1% | 0.99% | 1% | 1% |
| Net Income | -119.33M | -126.61M | -1.83B | -2.1B | -892.87M | -547.03M |
| Net Margin % | -2.2% | -1.65% | -5.83% | -4.41% | -3.55% | -2.41% |
| Net Income Growth % | - | -0.06% | -13.45% | -0.15% | 0.58% | 0.39% |
| Net Income (Continuing) | -119.86M | -126.72M | -1.84B | -2.11B | -892.87M | -547.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 8.79M | 8.68M | 62.01M | 0 | 0 | 0 |
| EPS (Diluted) | -4.15 | -4.00 | -55.53 | -50.20 | -18.40 | -10.54 |
| EPS Growth % | - | 0.04% | -12.88% | 0.1% | 0.63% | 0.43% |
| EPS (Basic) | -4.15 | -3.97 | -53.83 | -50.15 | -18.37 | -10.54 |
| Diluted Shares Outstanding | 28.73M | 31.87M | 34.01M | 42M | 48.61M | 51.89M |
| Basic Shares Outstanding | 28.73M | 31.65M | 32.95M | 41.93M | 48.53M | 51.89M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 511.93M | 426.54M | 1.72B | 1.45B | 1B | 602.74M |
| Cash & Short-Term Investments | 495.29M | 380.8M | 1.55B | 1.32B | 944.07M | 561.57M |
| Cash Only | 495.29M | 380.8M | 1.55B | 1.32B | 944.07M | 561.57M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 7.68M | 21.91M | 149.9M | 84.03M | 17.9M | 22.44M |
| Days Sales Outstanding | 51.72 | 104.3 | 174.34 | 64.2 | 25.98 | 36.08 |
| Inventory | 0 | 9.27M | 3.36M | 4.36M | 46K | 0 |
| Days Inventory Outstanding | - | 216.79 | 9.46 | 7.8 | 0.31 | - |
| Other Current Assets | 6.41M | 3.71M | 698K | 8.71M | 18.99M | 18.73M |
| Total Non-Current Assets | 185.39M | 248.61M | 347.94M | 1.09B | 663.59M | 774.71M |
| Property, Plant & Equipment | 63.13M | 121.44M | 145.77M | 718.79M | 394.99M | 598.15M |
| Fixed Asset Turnover | 0.86x | 0.63x | 2.15x | 0.66x | 0.64x | 0.38x |
| Goodwill | 1.86M | 1.86M | 21.31M | 60.21M | 49.24M | 0 |
| Intangible Assets | 3.84M | 3.29M | 21.64M | 111.04M | 82.74M | 72.51M |
| Long-Term Investments | 107.25M | 103.12M | 115.23M | 111.79M | 77.91M | 48.7M |
| Other Non-Current Assets | 9.31M | 18.9M | 43.99M | 87.41M | 58.71M | 55.34M |
| Total Assets | 697.32M | 675.15M | 2.07B | 2.54B | 1.67B | 1.38B |
| Asset Turnover | 0.08x | 0.11x | 0.15x | 0.19x | 0.15x | 0.16x |
| Asset Growth % | - | -0.03% | 2.07% | 0.23% | -0.34% | -0.17% |
| Total Current Liabilities | 40.07M | 73.22M | 134.76M | 172.96M | 163.86M | 107.27M |
| Accounts Payable | 2.44M | 13.89M | 8.19M | 10.45M | 9.32M | 14.17M |
| Days Payables Outstanding | - | 324.83 | 23.05 | 18.68 | 63.01 | 134.16 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 23.44M | 41.12M | 40.31M | 52.51M | 54.38M | 26.62M |
| Current Ratio | 12.77x | 5.83x | 12.79x | 8.38x | 6.11x | 5.62x |
| Quick Ratio | 12.77x | 5.70x | 12.76x | 8.36x | 6.11x | 5.62x |
| Cash Conversion Cycle | - | -3.74 | 160.75 | 53.32 | -36.72 | - |
| Total Non-Current Liabilities | 155.39M | 131.88M | 368.85M | 630.08M | 404.33M | 554.13M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 16.77M | 16.52M | 22.28M | 413.26M | 221.84M | 438.77M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 138.62M | 115.36M | 190.58M | 42.06M | 24.43M | 16.58M |
| Total Liabilities | 195.47M | 205.1M | 503.61M | 803.04M | 568.19M | 661.39M |
| Total Debt | 17.36M | 17M | 23.03M | 442.59M | 239.31M | 467.73M |
| Net Debt | -477.92M | -363.8M | -1.53B | -873.2M | -704.76M | -93.84M |
| Debt / Equity | 0.03x | 0.04x | 0.01x | 0.25x | 0.22x | 0.65x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -29.57x | -57.45x | -770.53x | -20839.17x | -9294.69x | -5954.86x |
| Total Equity | 501.85M | 470.05M | 1.57B | 1.74B | 1.1B | 716.06M |
| Equity Growth % | - | -0.06% | 2.33% | 0.11% | -0.37% | -0.35% |
| Book Value per Share | 17.47 | 14.75 | 46.09 | 41.34 | 22.57 | 13.80 |
| Total Shareholders' Equity | 493.06M | 461.38M | 1.51B | 1.74B | 1.1B | 716.06M |
| Common Stock | 79K | 129K | 161K | 190K | 5K | 5K |
| Retained Earnings | -341.27M | -467.88M | -2.3B | -4.4B | -5.29B | -5.84B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -1.72M | -2.63M | 1.48M | -1.81M |
| Minority Interest | 8.79M | 8.68M | 62.01M | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -44.66M | -135.83M | -253.82M | -252.2M | -295.5M | -319.58M |
| Operating CF Margin % | -0.82% | -1.77% | -0.81% | -0.53% | -1.18% | -1.41% |
| Operating CF Growth % | - | -2.04% | -0.87% | 0.01% | -0.17% | -0.08% |
| Net Income | -119.86M | -126.72M | -1.84B | -2.11B | -892.87M | -547.03M |
| Depreciation & Amortization | 10.76M | 13.86M | 29.08M | 42.55M | 71.55M | 63.02M |
| Stock-Based Compensation | 771K | 476K | 1.61B | 1.93B | 229.88M | 112.34M |
| Deferred Taxes | 54.73M | 0 | 30.21M | -14.61M | -801K | -936K |
| Other Non-Cash Items | -1.64M | 3.07M | -20.95M | -67.4M | 266.89M | 142.69M |
| Working Capital Changes | 10.58M | -26.52M | -61.54M | -37.01M | 29.84M | -89.67M |
| Change in Receivables | -1.84M | -14.23M | -114.09M | 55.02M | 50.07M | -4.72M |
| Change in Inventory | -2.22M | -2.74M | -626K | 164K | 0 | 0 |
| Change in Payables | 664K | 7.02M | -2.25M | -10.84M | -1.18M | 4.77M |
| Cash from Investing | -74.6M | -67.12M | -73.26M | -67.39M | -80.69M | -62.24M |
| Capital Expenditures | -22.22M | -57.82M | -56.52M | -52.27M | -40.8M | -62.54M |
| CapEx % of Revenue | 0.41% | 0.75% | 0.18% | 0.11% | 0.16% | 0.28% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -2.25M | -9.3M | 304K | -38.08M | -1.34M | 1.19M |
| Cash from Financing | 410.38M | 90.32M | 1.53B | 95.34M | -3.22M | -1.74M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 7K | 26K | 1.56B | -2.73M | -1.43M | -922K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -66.88M | -193.65M | -310.34M | -304.47M | -336.3M | -382.13M |
| FCF Margin % | -1.23% | -2.53% | -0.99% | -0.64% | -1.34% | -1.68% |
| FCF Growth % | - | -1.9% | -0.6% | 0.02% | -0.1% | -0.14% |
| FCF per Share | -2.33 | -6.08 | -9.13 | -7.25 | -6.92 | -7.36 |
| FCF Conversion (FCF/Net Income) | 0.37x | 1.07x | 0.14x | 0.12x | 0.33x | 0.58x |
| Interest Paid | 2.35M | 2.57M | 2.37M | 92K | 83K | 32K |
| Taxes Paid | 31K | 0 | 61K | 0 | 670K | 894K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -23.78% | -26.05% | -179.64% | -127.43% | -63.02% | -60.34% |
| Return on Invested Capital (ROIC) | -224.39% | -157.88% | -1870.12% | -366.74% | -103.28% | -82.75% |
| Gross Margin | 100% | 79.64% | 58.68% | 57.25% | 78.52% | 83.02% |
| Net Margin | -220.23% | -165.16% | -583.12% | -440.63% | -355.08% | -240.94% |
| Debt / Equity | 0.03x | 0.04x | 0.01x | 0.25x | 0.22x | 0.65x |
| Interest Coverage | -29.57x | -57.45x | -770.53x | -20839.17x | -9294.69x | -5954.86x |
| FCF Conversion | 0.37x | 1.07x | 0.14x | 0.12x | 0.33x | 0.58x |
| Revenue Growth | - | 41.48% | 309.4% | 52.21% | -47.36% | -9.71% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Service | 177.81M | 298.58M | 78.97M | 53.07M |
| Service Growth | - | 67.93% | -73.55% | -32.80% |
| Product | 23.04M | 35.45M | 28.95M | - |
| Product Growth | - | 53.88% | -18.35% | - |
| Foundry Revenue | 112.99M | 143.67M | - | - |
| Foundry Revenue Growth | - | 27.15% | - | - |
Ginkgo Bioworks Holdings, Inc. (DNA) reported $180.6M in revenue for fiscal year 2024. This represents a 233% increase from $54.2M in 2019.
Ginkgo Bioworks Holdings, Inc. (DNA) saw revenue decline by 9.7% over the past year.
Ginkgo Bioworks Holdings, Inc. (DNA) reported a net loss of $339.5M for fiscal year 2024.
Ginkgo Bioworks Holdings, Inc. (DNA) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
Ginkgo Bioworks Holdings, Inc. (DNA) had negative free cash flow of $187.2M in fiscal year 2024, likely due to heavy capital investments.